卖什么
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
商业模式拆解
工作流：什么输入变成什么输出？
LiliumX platform combines synthetic protein biology, high-throughput functional screening and AI to discover bispecific antibody-drug conjugates with "V-gate" logic; three oncology programs (VLN1 NSCLC/solid, VLN2 CRC, VLN3 pan-cancer, plus one unannounced) in discovery to preclinical.
经济账：省了什么，怎么收费？
未核实Pre-revenue biotech; value from pipeline assets and licensing/collaboration, funded by venture rounds (pre-A financing news).
渠道：怎么接触到客户？
Partnering: invites collaboration on its assets and discovery engine via LinkedIn or connect@valinktx.com.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2021 冬季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.